Majesta
US$ 24.35
fda compounding semaglutide crackdown news november 2025 Intensifies on GLP-1 FDA cracks down on 'misleading'
Description
Harlan D
He says companies need to find methods that give them freedom to operate that are not under patent to other companies
Specializes in hormone and metabolic treatments
Marketed as Ozempic for type 2 diabetes and Wegovy for weight management, semaglutide is administered as a once-weekly subcutaneous injection with a pre-filled pen device
It immediately clicked for me that I also wanted to improve my blood work and I should try a GLP-1. For the previous decade, Turners A1C had hovered in the prediabetic range
